NEWARK, N.J., Sept. 14, 2026 (GLOBE NEWSWIRE) — IDT Corporation (NYSE: IDT), a global provider of fintech and communications solutions, has scheduled its report of financial and operational results for the fourth quarter and full fiscal year 2026 (the three and twelve months ended July 31, 2026) on Monday, September 28, 2026.

IDT’s earnings release will be issued and posted on the IDT investor relations website (https://www.idt.net/investors-and–media) at approximately 4:30 PM Eastern.

IDT will host an earnings conference call beginning at 5:30 PM Eastern with management’s discussion of results followed by Q&A with investors. To listen to the call and participate in the Q&A, dial 1- 888-506-0062 (toll-free from the US) or 1-973-528-0011 (international) and provide the following access code: 266780.

A replay of the conference call will be available approximately three hours after the call concludes through October 12, 2026. To access the call replay, dial 1-877-481-4010 (toll-free from the US) or 1-919-882-2331 (international) and provide this replay passcode: 54497. The replay will also be accessible via streaming audio at the IDT investor relations website.

ABOUT IDT CORPORATION

IDT Corporation (NYSE: IDT) is a global provider of fintech, communications and AI-powered customer experience solutions through a portfolio of synergistic businesses: National Retail Solutions’ (NRS) point-of-sale (POS) platform enables independent retailers to process transactions and operate more effectively while providing advertisers and marketers with reach into underserved consumer markets; BOSS Money facilitates innovative international remittances and fintech payments solutions; net2phone provides businesses with AI-driven workflow and communications solutions to enhance customer experience;  BOSS Revolution  makes sharing prepaid products and services and speaking with friends and family around the world convenient and reliable; and, IDT Global and IDT Express enable communications companies to provision and manage international voice and SMS messaging.

Contact:
Bill Ulrey
IDT Investor Relations
Phone: (973) 438-3838
E-mail: invest@idt.net

###

Following years of proven success with a top-three U.S. life insurer, ID Dataweb will now expand the use of Trust Stamp’s proprietary IT2 tokenization technology across its existing and prospective customer base

ATLANTA, GA, Sept. 14, 2026 (GLOBE NEWSWIRE) — Trust Stamp (Nasdaq: IDAI), a global provider of AI-powered identity and privacy-enhancing technologies, today announced a major expansion of its strategic partnership with ID Dataweb™, a recognized leader in identity threat detection and risk mitigation. Building on three years of joint success serving one of the three largest life insurance providers in the United States, ID Dataweb will expand its use Trust Stamp’s biometric tokenization and identity fraud mitigation capabilities across its growing enterprise customer base.

The expanded relationship builds on a proven enterprise deployment and creates a scalable path for broader adoption of Trust Stamp’s technology through ID Dataweb. Trust Stamp’s patented Irreversibly Transformed Identity Token (IT2) technology transforms sensitive biometric data into secure, revocable identity tokens, helping organizations reduce the risks associated with storing biometric data while supporting privacy-conscious identity verification and fraud mitigation.

Trust Stamp President Andrew Gowasack commented, “Our long-standing work with ID Dataweb and a leading U.S. life insurance provider has demonstrated the technical and operational value of our technology in a demanding enterprise environment. Expanding our relationship with ID Dataweb represents an important next step in our commercial growth strategy and creates an opportunity to bring our IT2 technology to a broader range of enterprise customers. By combining Trust Stamp’s privacy-preserving tokenization capabilities with ID Dataweb’s identity threat detection platform and established enterprise reach, we can help more organizations strengthen identity trust while reducing the risks associated with sensitive biometric data.”

“Our relationship with Trust Stamp demonstrates the value of bringing together innovative, privacy-preserving technologies to solve real-world identity challenges,” said Matt Cochran, Chief Operating Officer at ID Dataweb. “After three years of successfully deploying Trust Stamp’s technology in a demanding enterprise environment, we see a significant opportunity to extend these capabilities to a broader set of customers. By integrating Trust Stamp’s biometric tokenization technology into the ID Dataweb platform, we can give organizations another powerful tool to establish identity trust, mitigate identity threats, and protect sensitive biometric information without introducing unnecessary friction into the customer experience.”

About Trust Stamp
Trust Stamp is a global provider of AI-powered services for use in multiple sectors including banking and finance, regulatory compliance, government, healthcare, real estate, communications, and humanitarian services. Its technology empowers organizations via advanced solutions that reduce fraud, tokenize and secure assets and data, and securely authenticate users while protecting personal privacy, reducing friction in digital transactions, and increasing operational efficiency. With team members from over twenty nationalities in ten countries across North America, Europe, Asia, and Africa, Trust Stamp trades on the Nasdaq Capital Market (Nasdaq: IDAI).

About ID Dataweb
ID Dataweb™ helps enterprises stay ahead of identity fraud and account-related threats with real-time detection and mitigation while maintaining a seamless experience for their workforce, third parties, and customers. The ID Dataweb SaaS platform combines adaptive identity verification methods, behavioral analytics, device and credential intelligence, and risk scoring. Backed by AI and expert insights, these capabilities proactively stop identity-based attacks, protect revenue, and strengthen compliance. Unlike static legacy identity tools, ID Dataweb delivers dynamic, multi-layered risk orchestration that adapts to evolving threats. Its low-code, cloud-native services deploy quickly, integrate seamlessly with existing IAM systems, and align with each customer’s policies.

ID Dataweb originated from the National Strategy for Trusted Identities in Cyberspace (NSTIC) initiative in 2011, which aimed to establish a user-centric digital ecosystem based on secure, privacy-preserving, and interoperable credentials rather than usernames and passwords. ID Dataweb’s founders brought this vision to market as a leading private-sector enabler of NSTIC. Today, ID Dataweb is a trusted partner to Fortune 1000 companies processing hundreds of millions transactions. Many leading identity security providers such as RSA, Ping Identity, CyberArk (now part of Palo Alto Networks), Okta, Auth0, Saviynt, and SailPoint partner with ID Dataweb to embed the company’s technology into their solutions or ensure seamless interoperability. In a world where digital trust is the new currency, robust identity threat detection and risk mitigation is no longer just a security measure it is a business imperative. That is where ID Dataweb makes a difference. For more information, please visit www.iddataweb.com.

Safe Harbor Statement: Caution Concerning Forward-Looking Remarks
All statements in this release that are not based on historical fact are “forward-looking statements” including within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The information in this announcement may contain forward-looking statements and information related to, among other things, the company, its business plan and strategy, and its industry. These statements reflect management’s current views with respect to future events-based information currently available and are subject to risks and uncertainties that could cause the company’s actual results to differ materially from those contained in the forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made.

Inquiries:
Trust Stamp: shareholders@truststamp.ai

Base Integration Marks Imperium’s First Expansion Beyond Ethereum Mainnet

WAYNE, Pa., Sept. 14, 2026 (GLOBE NEWSWIRE) — BTCS Inc. (Nasdaq: BTCS) (“BTCS” or the “Company”), short for Blockchain Technology Consensus Solutions, a company focused on decentralized finance and blockchain infrastructure operations, today announces that Imperium, the Company’s decentralized finance (“DeFi”) business line, has expanded onto Base, an Ethereum Layer-2 network created by Coinbase. Base runs on top of Ethereum and is designed to make transactions faster and cheaper, which has helped it become one of the most widely used blockchain networks.

“We continue to explore new opportunities that we believe can generate scalable high-margin revenue, and expanding Imperium into a multi-chain strategy is a clear example of that. Operating across multiple networks and assets lets us dynamically provide liquidity where volume and demand shift, and Base is our first step beyond Ethereum mainnet,” said Charles Allen, CEO of BTCS. “Imperium’s growth accelerated in the third quarter. We went from approximately $8 million in assets deployed in paired liquidity pools (“LP”) at the end of Q2 to approximately $36 million today. The growth of our paired LP assets puts us in a strong position to exceed our $6 million gross profit target for the year.”

Launched in 2025, Imperium is BTCS’s DeFi business line, through which the Company generates revenue by actively deploying digital assets (currently ETH and stablecoins) into smart contract-based protocols that facilitate decentralized lending, borrowing, liquidity provisioning, and other financial activities. Rather than relying on a single approach, Imperium spans a range of evolving strategies. Unlike staking, which is primarily a yield play with protocol-set rewards and lock-up requirements, Imperium’s DeFi approach allows BTCS to dynamically allocate assets across protocols and networks based on prevailing market conditions, profit potential, and risk, positioning the Company to scale revenue and improve profitability.

“Base has grown into one of the largest Ethereum Layer-2 networks, with over $12 billion in on-chain assets today. We continue to see strong transaction volume and rising demand on Base, and that scale and activity make it a compelling environment for Imperium to pursue high-margin revenue,” said Ben Hunter, Chief Technology Officer of BTCS.

Integrating Base into Imperium’s operations extends the Company’s revenue-generating DeFi activities into an additional, widely used Ethereum Layer-2 ecosystem, further diversifying the Company’s footprint beyond Ethereum mainnet. The Company believes this integration supports its objective of driving high-margin, scalable revenue, as Imperium can generate and compound revenue across a broader set of opportunities. Base is one step in a broader roadmap: BTCS is actively evaluating additional strategies for Imperium that it believes may further scale the business.

About BTCS:

BTCS Inc. (“BTCS” or the “Company”), short for Blockchain Technology Consensus Solutions, is a U.S.-based Ethereum-first blockchain technology company committed to driving scalable revenue and asset accumulation through its hallmark strategy, the DeFi/TradFi Accretion Flywheel, an integrated approach to capital formation and blockchain infrastructure. By combining decentralized finance (“DeFi”) and traditional finance (“TradFi”) mechanisms with its blockchain infrastructure operations, comprising NodeOps (staking), Builder+ (block building), and Imperium (DeFi deployments), BTCS offers a unique opportunity for blockchain exposure, driven by recurring on-chain revenue generation and an Ethereum-focused strategy. Discover how BTCS offers exposure to Ethereum and its on-chain economy through the public markets at www.btcs.com.

Forward-Looking Statements:

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements include, but are not limited to, statements regarding the expansion of Imperium onto Base, growth in the Company’s deployed digital assets, revenue expectations (including from Imperium), profitability and margin targets (including the Company’s $6 million gross profit target for the year), the Company’s ability to generate and compound revenue across multiple networks and protocols, market positioning, business strategy, regulatory developments affecting digital assets, and expectations for digital asset markets. Words such as “may,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “predict,” “intend,” “target,” “seek,” “positioned” or similar expressions identify forward-looking statements. These statements are based on current expectations and assumptions and are subject to risks and uncertainties, including volatility in digital asset markets, including the market price of ETH and other digital assets, and concentration risk from the Company’s Ethereum-first strategy; regulatory developments affecting digital assets and blockchain technology, including regulation of DeFi protocols and Layer-2 networks; competition in DeFi markets; operational risks associated with Imperium, including smart contract vulnerabilities, DeFi protocol failures, counterparty risks, impermanent loss and liquidity risks associated with DeFi lending, borrowing, and liquidity provision activities, and the Company’s reliance on third-party DeFi protocols; risks related to the Company’s use of leverage and collateralization requirements; the risk that the Company may not achieve its revenue or profitability targets, including the $6 million gross profit target; technological implementation challenges, cybersecurity risks, and potential loss or theft of digital assets; risks related to the Ethereum network and Layer-2 networks such as Base, including fluctuations in transaction volumes and blockspace demand, and changes in network protocols, consensus mechanisms, or gas fee structures; risks that the Company’s multi-chain expansion strategy may not produce the anticipated benefits; general economic and market conditions; and other risks set forth in the Company’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2025. Undue reliance should not be placed on forward-looking statements, which speak only as of the date of this release. The Company expressly disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable securities laws.

For more information, follow us on:

X: https://x.com/NasdaqBTCS
LinkedIn: https://www.linkedin.com/company/nasdaq-btcs
Facebook: https://www.facebook.com/NasdaqBTCS

Investor Relations:

Charles Allen – CEO
X: @Charles_BTCS
Email: ir@btcs.com

A Special Committee of independent directors carefully reviewed Forward’s all-stock proposal before determining it was not in the best interests of shareholders 

SkyAI reaffirms commitment to its Solana DAT strategy and continues to hold more than two million SOL with no debt

Board reiterates commitment to transparency and strong governance

NEW YORK, Sept. 14, 2026 (GLOBE NEWSWIRE) — SkyAI, Inc. (Nasdaq: SKYA) (“SkyAI” or the “Company”), a financial technology company with a Solana digital asset treasury (“DAT”) that is building an agentic finance platform, today issued the following statement regarding a recent public letter from Forward Industries, Inc. (“Forward”).

SkyAI’s Board of Directors (the “Board”) remains committed to acting in the best interests of all shareholders. The Board believes shareholders should have the full facts and context as they consider the matters before them at the upcoming Annual Meeting.

The Special Committee thoroughly reviewed Forward’s acquisition proposal and determined it was not in the best interests of shareholders

The Board carefully evaluates opportunities that may enhance shareholder value. After receiving Forward’s unsolicited, non-binding, all-stock acquisition proposal in June, the Board established a Special Committee consisting entirely of independent directors to carefully evaluate the proposal.

The Special Committee, with the assistance of independent advisors, considered factors such as the terms and structure of the proposal, including its all-stock nature and associated risks and uncertainties, as well as SkyAI’s standalone prospects.

Following its review, the Special Committee unanimously concluded that Forward’s proposal was not in the best interests of shareholders and that continuing to execute SkyAI’s standalone strategy offered a more compelling opportunity for long-term value creation. The full Board has subsequently reached the same conclusion.

The Board stands by its decision and remains committed to guiding and overseeing SkyAI’s strategy for the benefit of all shareholders.

SkyAI reaffirms its commitment to its Solana DAT strategy

SkyAI continues to hold more than two million SOL as its primary treasury reserve asset. Nearly all of the Company’s SOL is staked with institutional validators, enabling SkyAI to participate directly in securing the Solana network while generating staking revenue. SkyAI currently intends that revenue from the DAT strategy will fund cash operating expenses including DAT operations, corporate expenses and R&D.

From the launch of its treasury strategy in August 2025 through June 30, 2026, SkyAI recognized more than $12 million in staking revenue, net of validator commissions. As of that date, the Company also held approximately $12.1 million in cash and stablecoins and had no outstanding debt. Over the ten epochs from August 23 to September 8, 2026, SkyAI’s Solana validator generated an annualized gross yield of 6.01% in SOL, compared with a stake-weighted average of 5.57% across all Solana validators over the same epochs1.

The Company’s conviction in Solana extends beyond its treasury holdings. SkyAI is building its agentic finance platform on Solana and believes the network’s speed, cost structure, developer ecosystem, and growing application activity make it well positioned to support the next generation of on-chain financial and AI products.

Continued growth across the Solana ecosystem reinforces that conviction. Solana has led all blockchains in application revenue for nine consecutive quarters through the second quarter of 2026, and applications built on Solana generated more revenue in August than applications on any other blockchain.

SkyAI believes its combination of a substantial SOL treasury, staking participation, and technology development on Solana creates differentiated exposure to the continued growth of the ecosystem.

The Board is committed to strong governance and oversight

The Board recognizes the importance of effective governance and transparency. The Company has publicly disclosed its relationships and arrangements with its consultant and strategic advisor in prior filings. These agreements were reviewed by the Board, with the assistance of independent advisors, and were entered into by the Company on August 25, 2025, prior to the closing of the August 2025 private placement (the “PIPE”) on August 28, 2025.

The strategic advisor warrants issued to SOL Markets cover 6,321,367 shares, calculated as 10% of the shares issued in the PIPE. The approximately $101.3 million figure cited in Forward’s letter is not a cash payment to the strategic advisor; rather, it represents the grant-date accounting fair value required to be recognized under U.S. GAAP for the warrants issued in August 2025. The strategic advisor has not sold any shares or warrants of the Company and continues to hold its full position without any hedging instruments.

SkyAI’s related-party transactions policy requires Audit Committee approval of covered transactions involving directors, officers, 5% shareholders and their affiliates. The Board will continue to oversee related-party matters and act in the best interests of shareholders.

The Board will continue to evaluate the Company’s governance practices as SkyAI grows and evolves.

The 2026 Equity Incentive Plan aligns talent with long-term shareholder value and reflects market norms

SkyAI’s transformation from its legacy medical device business into a DAT and financial technology company requires new capabilities across digital assets, artificial intelligence, blockchain infrastructure, and financial services. Attracting and retaining that talent requires SkyAI to offer compensation that is competitive with other technology and DAT companies while aligning employees, executives, and directors with long-term shareholders.

In determining the size of the proposed 2026 Equity Incentive Plan, the Board considered the remaining capacity under the existing plan, anticipated hiring and retention requirements, projected future equity needs, and equity plan authorizations at comparable DAT companies and technology issuers. Importantly, the proposed authorization remains below the median equity incentive plan authorized by comparable DAT companies when measured on a fully diluted basis, which includes pre-funded warrants and other warrants exercisable at par value.

The Board believes the proposed plan represents a measured approach that allows SkyAI to attract and retain talent, aligns compensation with long-term shareholder value, and preserves cash for operations and execution of the Company’s strategy.

SkyAI’s Board and management are focused on unlocking value for all shareholders

Over the past year, SkyAI has undertaken a significant transformation. The Company has established a substantial Solana treasury, generated staking revenue from those assets, and is building an agentic finance platform.

The Board remains confident that the continued execution of the Company’s strategy will unlock significant value for shareholders.

The Board unanimously recommends that SkyAI shareholders vote FOR each of the Company’s director nominees and FOR the 2026 Equity Incentive Plan at the Annual Meeting on September 18, 2026.

YOUR VOTE IS IMPORTANT

To ensure your shares are represented at the Annual Meeting, please submit your vote TODAY: Vote “FOR” All of SkyAI’s Highly Qualified Nominees

If you have any questions or require any assistance with voting your shares, please call the Company’s proxy solicitor:

Advantage Proxy, Inc
P.O. Box 10904
Yakima, WA 98909
Attn: Karen Smith
Toll Free Telephone: (877) 870-8565
Main Telephone: (206) 870-8565
E-mail: ksmith@advantageproxy.com

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements in this release other than statements of historical fact are forward-looking statements, including statements regarding the Company’s strategy and product roadmap and the potential opportunities such initiatives may create. Forward-looking statements are based on current expectations, assumptions, and beliefs, and involve risks and uncertainties that could cause actual results to differ materially.

These risks and uncertainties include, among others: the Company’s ability to successfully execute its digital asset treasury and AI technology strategies; the price of SOL and the level of staking rewards; the outcome of the Annual Meeting and any further actions by Forward or other shareholders; and general market, economic, and business conditions. Additional risks are described in the “Risk Factors” section of the Company’s filings with the Securities and Exchange Commission (the “SEC”), which are available on the SEC’s website at www.sec.gov.

Forward-looking statements speak only as of the date of this press release. The Company undertakes no obligation to update or revise these statements, whether as a result of new information, future developments, or otherwise, except as required by law.

Important Additional Information and Where to Find It 

The Company has filed a definitive proxy statement with the SEC in connection with its solicitation of proxies for the Annual Meeting. Shareholders are able to obtain the Company’s proxy statement, any amendments or supplements to the proxy statement and other documents filed by the Company with the SEC at no charge at the SEC’s website at www.sec.gov. Copies are also available at no charge at the Company’s website at https://www.skyai.co/investors/all-sec-filings.

Participants in the Solicitation

The Company, its directors and certain of its executive officers are deemed to be “participants” (as defined in Schedule 14A under the Exchange Act of 1934, as amended) in the solicitation of proxies from the Company’s shareholders in connection with matters to be considered at the Annual Meeting of shareholders. Information about the names of the Company’s directors and officers, and certain other individuals and their respective interests in the Company by security holdings or otherwise, and their respective compensation, is set forth in the Company’s Proxy Statement on Schedule 14A in connection with the Annual Meeting and the Company’s Annual Report on Form 10-K.  The Company has also engaged the services of Advantage Proxy, Inc. to solicit proxies from its shareholders.  

About SkyAI

SkyAI, Inc. (Nasdaq: SKYA), formerly Sharps Technology, Inc., is building Agentic Finance for the Global South that will combine stablecoin rails on Solana with AI to deliver financial access, education, and actionable intelligence to the billions of underbanked users across Asia, Latin America, and Africa. For additional information, please visit www.theskyai.co.

Media Contact
Edelman Smithfield
SkyAI@edelmansmithfield.com

_________________________________
1 Data: Trillium (trillium.so), per-epoch validator and network rewards, epochs 1021 to 1030 (August 23 to September 8, 2026), pulled September 9, 2026. Network figures are stake-weighted across all validators. Gross yields comprise inflation rewards, block rewards (priority fees) and MEV before validator commission.

RMAT Designation Supported by Positive Interim Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 which Demonstrated Reduced Arrhythmia Burden 

Additional Data and Updates on Regulatory Discussions Anticipated in 4Q 2026

SOUTH SAN FRANCISCO, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) — Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to TN-401, Tenaya’s gene therapy candidate for the treatment of PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC).

“RMAT designation underscores the continued recognition by regulators of the seriousness of PKP2-associated ARVC and the potential of TN-401 gene therapy to change the course of disease by addressing its underlying cause. This designation is supported by the encouraging interim data generated to date from our RIDGE-1 trial, which demonstrated clinically meaningful reductions in daily rates of PVCs and NSVTs, as well as a favorable tolerability profile,” said Faraz Ali, Chief Executive Officer of Tenaya Therapeutics. “Together with Fast Track and Orphan Drug designations, RMAT enhances our ability to engage with the FDA as we strive to advance TN-401 toward a pivotal trial in order to bring this potentially transformative treatment to patients as quickly as possible. We look forward to sharing additional data from RIDGE-1 in the fourth quarter and providing an update on our ongoing discussions with regulators regarding pivotal trial plans for TN-401.”

Tenaya’s RMAT application included data presented at the American Society for Gene and Cell Therapy (ASGCT) Annual Meeting in May 2026. Interim results from the RIDGE-1 clinical trial of TN-401 showed improvements in multiple electrical stability measures, including reduced rates of premature ventricular contractions (PVCs) and non-sustained ventricular tachycardias (NSVTs), two of the most frequently occurring forms of ventricular arrhythmias that characterize ARVC.

RMAT designation is an FDA expedited program intended to facilitate the development and review of regenerative medicine therapies for serious conditions where preliminary clinical evidence indicates the potential to address unmet medical needs. RMAT designation provides enhanced opportunities for interaction with the FDA, including early and ongoing guidance regarding clinical development, manufacturing and potential regulatory pathways, and it may provide eligibility for accelerated approval, priority review and rolling review.

About PKP2-Associated ARVC
Plakophilin-2 (PKP2) mutations are the most common genetic cause of arrhythmogenic right ventricular cardiomyopathy (ARVC, also known as arrhythmogenic cardiomyopathy or ACM), occurring in approximately 40 percent of the overall ARVC population. The prevalence of PKP2-associated ARVC is estimated at more than 70,000 people in the U.S. alone.

In PKP2-associated ARVC, mutations of the PKP2 gene results in insufficient expression of a protein needed for the proper functioning of the desmosomal complex that maintains physical connections and electrical signaling between heart muscle cells. As the desmosome structure degrades, cardiac muscle cells are replaced by fibrofatty tissue and electrical pulses in the heart become unstable, resulting in life potentially threatening heart rhythms. ARVC symptoms include arrhythmias, palpitations, lightheadedness, dizziness and fainting. It is typically diagnosed before age 40, and sudden cardiac arrest due to ventricular arrhythmia is frequently the first manifestation of disease. Current treatments include anti-arrhythmic medications, implantable cardioverter-defibrillators (ICDs) and ablation procedures, which do not address the underlying genetic cause of disease.

About TN-401 Gene Therapy and the RIDGE-1 Clinical Trial
TN-401 is an investigational AAV9-based gene therapy being developed for the treatment of ARVC due to mutations in the PKP2 gene. AAV9 was selected as the vector for delivery of Tenaya’s PKP2 gene therapy based on its extensive clinical and commercial safety record and demonstrated ability to target heart muscle cells. TN-401 has received Orphan Drug and Fast Track Designations from the U.S. Food and Drug Administration, as well as PRIME designation from the European Medicines Agency. Tenaya’s development of TN-401 is supported in part by a grant from the California Institute for Regenerative Medicine (CIRM).

The RIDGE-1 Phase 1b/2 clinical trial ClinicalTrials.gov (NCT06228924) of TN-401 in patients with PKP2-associated ARVC is a multi-center, open-label, dose escalation study being conducted in the U.S. and UK. RIDGE-1 is intended to assess the safety, tolerability and preliminary clinical efficacy of a one-time intravenous infusion of TN-401. RIDGE-1 seeks to enroll up to fifteen adults who have been diagnosed with PKP2-associated ARVC, have an ICD and are at increased risk for arrhythmias as determined by premature ventricular count (PVC) during screening. As part of its TN-401 development program, Tenaya is also conducting RIDGE ClinicalTrials.gov (NCT06311708), believed to be the largest natural history study of adults with PKP2-associated ARVC.

To learn more about gene therapy for ARVC and the RIDGE-1 clinical trial, please visit ARVCstudies.com.

About Tenaya Therapeutics
Tenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver potentially curative therapies that address the underlying drivers of heart disease. Tenaya’s pipeline includes clinical-stage candidates TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM); TN-401, a gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC); and TN-301, a highly specific small molecule HDAC6 inhibitor with broad potential clinical utility in cardiac, metabolic and muscular conditions, including heart failure with preserved ejection fraction (HFpEF) and Duchenne muscular dystrophy (DMD). Tenaya has employed a suite of integrated internal capabilities including modality agnostic target discovery and validation, to generate a portfolio of novel medicines based on genetic insights, aimed at the treatment of both rare genetic disorders and more prevalent heart conditions. For more information, visit www.tenayatherapeutics.com.

Forward Looking Statements

This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Words such as “anticipated,” “potential,” “strive,” “look forward,” “may” and similar expressions are intended to identify forward-looking statements. Such forward-looking statements include, among other things, the plan and related timing to share additional data from RIDGE-1 and provide an update on regulatory discussions regarding pivotal trial plans for TN-401; the potential for TN-401 gene therapy to change the course of PKP2-associated ARVC by addressing the underlying cause of disease; the potential development and regulatory review opportunities for TN-401 due to RMAT designation; Tenaya’s efforts to advance TN-401 toward a pivotal trial; and statements by Tenaya’s Chief Executive Officer. The forward-looking statements contained herein are based upon Tenaya’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. These forward-looking statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, including but not limited to: availability of data at the referenced time; the timing and progress of RIDGE-1 and Tenaya’s other ongoing clinical trials; the potential failure of TN-401 and Tenaya’s other product candidates to demonstrate safety and/or efficacy in clinical testing; the potential for the FDA and/or other regulatory agencies to conclude at any time that TN-401 may not have an appropriate risk/benefit profile; changes in Tenaya’s plans to develop and commercialize TN-401 and its other product candidates; the potential for RIDGE-1 clinical trial results to differ from preclinical, interim, preliminary, topline or expected results; risks associated with the process of discovering, developing and commercializing therapies that are safe and effective for use as human therapeutics; Tenaya’s ability to develop, initiate or complete preclinical studies and clinical trials, and obtain approvals, for any of its product candidates; Tenaya’s continuing compliance with applicable legal and regulatory requirements; Tenaya’s ability to raise any additional funding it will need to continue to pursue the clinical development of TN-401 and its other product candidates, as well as Tenaya’s general business plans; Tenaya’s reliance on third parties; Tenaya’s manufacturing, commercialization and marketing capabilities and strategy; the loss of key scientific or management personnel; competition in the industry in which Tenaya operates; Tenaya’s ability to obtain and maintain intellectual property protection for its product candidates; general economic and market conditions; and other risks. Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in Tenaya’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, and future documents that Tenaya files from time to time with the Securities and Exchange Commission. These forward-looking statements are made as of the date of this press release, and Tenaya assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Tenaya Contacts
Michelle Corral
VP, Corporate Communications and Investor Relations
IR@tenayathera.com

Investors
Anne-Marie Fields
Precision AQ
annemarie.fields@precisionaq.com

Media
Wendy Ryan
Ten Bridges Communications
wendy@tenbridgecommunications.com

Advanced multi-omics data analysis and biostatistical expertise to sharpen target and biomarker decisions across the platform

PRINCETON, N.J., and NEW HAVEN, Conn., Sept. 14, 2026 (GLOBE NEWSWIRE) — Niki BioSolutions, Inc. (NASDAQ: NIKI) (“Niki” or the “Company”), a clinical-stage life sciences company focused on unmet medical needs and genomic and biomarker testing solutions, today announced that its wholly owned subsidiary, DiamiR Biosciences Corp. (“DiamiR”), has engaged Fios Genomics, a specialist provider of bioinformatics and biostatistics services, to perform bioinformatics and statistical analysis in support of the Company’s Alzheimer’s disease program. Under the engagement, Fios Genomics will analyze and interpret data generated across the program to help Niki BioSolutions advance its Alzheimer’s assays through the development pipeline.

Alzheimer’s disease affects tens of millions of people worldwide and remains one of the most significant unmet needs in medicine. Robust, reproducible analysis of complex biological datasets is essential to identifying meaningful biological signals, validating targets and biomarkers, and making well-informed decisions at each stage of development. Fios Genomics brings deep experience in the analysis of genomic, transcriptomic, proteomic, and other large, complex biological datasets, together with rigorous statistical methodology, to help translate raw data into actionable insight.

“Engaging Fios Genomics is an important step forward for our Alzheimer’s program,” said Alidad Mireskandari, Ph.D., President and Chief Operating Officer of Niki BioSolutions. “The datasets generated in this project are large and complex, and getting the analysis right is critical to the decisions we make next. Fios Genomics has a strong track record of delivering high-quality, independent bioinformatics and statistical analysis for life sciences organizations, and its expertise allows our team to stay focused on advancing the science. We look forward to a productive collaboration as we work to bring new options to people at risk of or living with Alzheimer’s disease.”

As part of the engagement, Fios Genomics will provide end-to-end analytical support, including data quality assessment, statistical analysis and interpretation of current datasets, and the delivery of clear, decision-ready reports to Niki BioSolutions’ research and development team. The work is expected to inform target and biomarker prioritization and support the design of subsequent validation studies within the pipeline.

About Niki BioSolutions

Niki BioSolutions is a clinical-stage life sciences company focused on unmet medical needs and on providing high-quality genomic and biomarker testing solutions to healthcare providers, research institutions, and life sciences organizations through its CLIA-certified, CAP-accredited laboratory. The company combines proprietary technologies with a commitment to scientific rigor to support precision medicine across a range of therapeutic areas, including brain health and oncology. Niki BioSolutions collaborates with leading academic centers, disease foundations, and biopharma companies.

About Fios Genomics

Fios Genomics is a specialist provider of bioinformatics and biostatistics services to the pharmaceutical, biotechnology, and academic sectors. The company supports research and development programs with data analysis and interpretation across genomics, transcriptomics, proteomics, and other high-throughput data types, from early discovery through clinical development. Fios Genomics is headquartered in Edinburgh, United Kingdom. For more information, visit www.fiosgenomics.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements often use words such as “believe,” “may,” “will,” “estimate,” “target,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “propose,” “plan,” “project,” “forecast,” “predict,” “potential,” “seek,” “future,” “outlook,” and similar variations and expressions. Forward-looking statements are those that do not relate strictly to historical or current facts. Examples of forward-looking statements may include, among others, Niki BioSolutions’ ability to successfully operate its business and provide value to stockholders; Niki BioSolutions’ future financial, business and operating performance and goals; annualized recurring revenue and customer retention; ongoing or future ability to maintain or improve its financial position, cash flows, and liquidity and its expected financial needs; potential financing and ability to obtain financing; acquisition strategy and proposed acquisitions and, if completed, their potential success and financial contributions; strategy and strategic goals, including being able to capitalize on opportunities; expectations relating to Niki BioSolutions and its industry, outlook and market trends; total addressable market and serviceable addressable market and related projections; plans, strategies and expectations for increasing revenue and executing growth initiatives. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity and development of the industries in which Niki BioSolutions operates may differ materially from those made in or suggested by the forward-looking statements. Therefore, investors should not rely on any of these forward-looking statements. Factors that may cause actual results to differ materially include changes in the markets in which Niki BioSolutions operates, the financial markets, economic, business and regulatory factors, and other factors, such as Niki BioSolutions’ ability to execute on its strategies. More detailed information about risk factors can be found in the registration statement on Form S-4 filed with the Securities and Exchange Commission (the “SEC”) on October 6, 2025 (File No. 333-290742), and in other reports filed under the company’s prior name, Aptorum Group Limited, and that will be filed by Niki BioSolutions with the SEC. Niki BioSolutions does not undertake any duty to update forward-looking statements after the date of this press release.

Investor Contact:

Lytham Partners, LLC
Ben Shamsian
646-829-9701
shamsian@lythampartners.com

The joint project is designed to validate next-generation power architecture for GPU systems, an important precursor to large-scale manufacturing and industry certification

SAN FRANCISCO, Sept. 14, 2026 (GLOBE NEWSWIRE) — Exascale Labs Holdings Inc. (“Exascale”) (Nasdaq: XLAB), a next-generation AI infrastructure provider, today announced that it has entered into a non-binding Letter of Intent with Compal Electronics, Inc. (“Compal”) (TWSE: 2324), a global IT solutions leader, to jointly develop a U.S.-based platform for next-generation GPU systems. The platform will be built on a native 800-volt direct current (VDC) architecture using solid-state transformer (SST) technology to test how GPU computing systems perform in a fully integrated AI data center environment.

The platform will combine Compal’s production-grade GPU server platforms and liquid cooling systems with Exascale’s Modular Data Center (MDC) and SST power architecture to validate power, compute, cooling, and controls as an integrated system. As GPU rack densities increase, the industry is exploring 800 VDC to reduce conversion stages and improve power distribution efficiency. At present, integrated physical validation across power, servers, cooling, and software controls remains limited. The project is designed to bring both companies’ production-grade hardware into a shared testing environment, allowing electrical, thermal, mechanical and software interfaces to be engineered and validated together before deployment.

A production-grade validation platform for next-generation GPU infrastructure

Under the anticipated division of responsibilities, Compal will provide the U.S. project site, GPU servers, and liquid cooling systems. Exascale will design the modular data center system, SST-based power architecture and related software systems, and will lead the end-to-end deployment, commissioning, and testing of the platform.

“The goal is to validate native 800 VDC across a complete data center system,” said Dr. Hoansoo Lee, Chief Executive Officer of Exascale. “Compal’s planned contribution of the site, GPU servers and cooling systems will allow us to test our SST power architecture and modular infrastructure alongside the equipment they are intended to support. That integration is an important step toward commercial deployment.”

Expected platform capabilities

  • Validating SST operational availability in a data-center-grade, end-to-end environment, while accumulating the experience and data needed to support volume production and the UL certification process;
  • Conducting native 800 VDC compatibility testing and pre-shipment power-on testing for GPU servers;
  • Providing a test and validation environment for upstream and downstream ecosystem partners; and
  • Accumulating experience and data toward the development of standardized, data-center-grade native 800 VDC solutions and the attainment of industry certifications.

From joint development to product acquisition

Following completion of the platform and successful acceptance testing agreed by the parties, Compal intends, subject to the definitive agreement, to acquire the portion of the platform developed and provided by Exascale, including the SST systems, power distribution equipment, modular data center facilities and software use licenses. The definitive agreement would establish the final acquisition scope, purchase price, closing conditions and other commercial terms.

“Power, compute, and cooling all have to work as one system. Native 800 VDC is not simply a new power input for the server— it requires the server, power system, cooling, and controls to operate as an integrated system,” said Alan Chang, VP and GM of ISBG of Compal. “By integrating our GPU servers and cooling systems into the development process from the outset, we can validate the complete infrastructure under real operating conditions and build a repeatable architecture that can support future high-density AI deployments at scale.”

About Exascale

Exascale is a next-generation AI infrastructure provider operating a software-defined GPU compute platform and related AI infrastructure solutions. Its business includes Token Factory, GPU-as-a-service, GPU cluster management and optimization, and infrastructure solutions spanning modular data centers, HVDC power, high-density cooling, and data center interconnectivity. Exascale’s platform supports large-scale AI workloads, including training, fine-tuning, high-concurrency inference, and API-based token generation. For more information, visit www.exascalelabs.ai.

About Compal

Founded in 1984, Compal is a leading global manufacturer of computers and smart devices and a Forbes Global 2000 company, partnering with top-tier brands worldwide. Compal has expanded into cloud servers, automotive electronics, smart medical and healthcare, and advanced communication solutions. Headquartered in Taipei, Taiwan, Compal operates globally across the United States, Taiwan, China, Vietnam, Mexico, Brazil, and Poland. Learn more at https://www.compal.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as “anticipate,” “believe,” “can,” “continue,” “could,” “expect,” “intend,” “may,” “plan,” “project,” “seek,” “should,” “will,” and similar expressions. These statements include, without limitation, statements regarding the anticipated development, deployment, commissioning, testing and capabilities of the proposed platform, the potential validation of a native 800 VDC architecture, the anticipated contributions and responsibilities of the parties, the potential benefits, performance, efficiency, scalability and commercial applications of the proposed platform and related technologies, and Compal’s intention to acquire certain portions of the platform developed and provided by Exascale. These statements are based on current expectations and assumptions, and involve risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements, including, among others, the ability of the parties to successfully develop and integrate the proposed platform, the ability to achieve anticipated power, thermal, mechanical or software integration objectives, the ability to commercialize the resulting technology, competition in AI infrastructure and data-center markets, financing and capital requirements, and other risks and uncertainties described from time to time in Exascale’s filings with the Securities and Exchange Commission. In addition, the Letter of Intent is non-binding, and there can be no assurance that the parties will enter into a definitive agreement, that the proposed platform will be completed or accepted, or that Compal will ultimately acquire any portion of the platform.

If any of these risks materialize or the assumptions prove incorrect, actual results could differ materially from the results contained in or implied by these forward-looking statements. There may be additional risks that Exascale does not presently know or cannot currently anticipate or that Exascale currently believes are immaterial that could also cause actual results to differ materially from those contained in or implied by the forward-looking statements.

The forward-looking statements speak only as of the date of this press release. Exascale undertakes no obligation to update or revise any forward-looking statements, except as required by law.

Investor Contact

Nick Hresko-Staab
KCSA Strategic Communications
Exascale@KCSA.com

Media Contact

Hannah Erger
KCSA Strategic Communications
Exascale@KCSA.com

Initial Advance of $2.5 Million to Realbotix LLC to Support Growth and Working Capital; Non-Interest Bearing Facility Is Automatically Cancelled and Discharged in Full Upon Closing of Pending Acquisition

CINCINNATI, Ohio, Sept. 14, 2026 (GLOBE NEWSWIRE) — Onconetix, Inc. (Nasdaq: ONCO) (“Onconetix” or the “Company”) today announced that it has provided a strategic bridge financing facility of up to $5,000,000 to Realbotix LLC (“Realbotix”), the target of its previously announced pending acquisition, to support Realbotix’s growth and working capital needs while the parties advance toward closing of the acquisition. The financing was provided in connection with the Share Exchange Agreement between the two companies, announced on February 12, 2026.

The facility provides for an aggregate principal amount of up to $5,000,000, with an initial advance of $2,500,000.

The facility is non-interest bearing prior to the closing of the Share Exchange Agreement. Upon closing of the acquisition, the facility and all obligations thereunder will be automatically cancelled and discharged in full. In addition, the cash required at closing of the acquisitions will be reduced by the total principal advanced under the facility plus an additional $500,000. If the Share Exchange Agreement is terminated, interest accrues at 12% per annum from the date of termination. A description of the Note is included in Onconetix’s Current Report on Form 8-K filed with the SEC on [DATE], 2026. The full text of the Note is filed as an exhibit to that report and is available at www.sec.gov.

As previously announced on February 12, 2026, Onconetix entered into the Share Exchange Agreement to acquire 100% of the issued and outstanding equity interests of Realbotix LLC in an all-stock transaction. The combined company is expected to trade on Nasdaq following closing, which is subject to Onconetix shareholder approval, required regulatory approvals, and other closing conditions.

This communication is being provided for informational purposes only. Investors are cautioned not to place undue reliance on forward-looking or projected information.

About Onconetix, Inc.

Onconetix, Inc. (Nasdaq: ONCO) is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative oncology solutions. Onconetix owns Proclarix®, an in vitro diagnostic test for prostate cancer originally developed by Proteomedix and approved for sale in the European Union under the IVDR, which it anticipates will be marketed in the U.S. as a lab developed test through its license agreement with Labcorp. For more information, visit www.onconetix.com.

About Realbotix LLC

Realbotix LLC is a wholly-owned subsidiary of Realbotix Corp. (TSX-V: XBOT; Frankfurt: 76M0.F; OTC: XBOTF) and the target of Onconetix’s pending acquisition. Realbotix LLC develops AI-powered humanoid robots designed for human interaction across enterprise and consumer environments. Manufactured in the United States, Realbotix’s patented AI and robotics technologies enable lifelike expressions, motion, vision, and social engagement. For more information, visit www.realbotix.ai.

Additional Information and Where to Find It

In connection with the proposed transaction between Realbotix and Onconetix, Onconetix intends to file with the SEC a Registration Statement on Form S-4 (the “Registration Statement”) to register the common stock to be issued by Onconetix in connection with the proposed transaction. The Registration Statement will include a proxy statement of Onconetix and a prospectus of Onconetix (the “Proxy Statement/Prospectus”), and each of Realbotix and Onconetix may file with the SEC other relevant documents concerning the proposed transaction. After the Registration Statement is declared effective, the definitive Proxy Statement/Prospectus will be sent to the stockholders of Onconetix to seek their approval of the proposed transaction. This is not a substitute for the Registration Statement, the Proxy Statement/Prospectus or any other relevant documents that Realbotix or Onconetix has filed or will file with the SEC. BEFORE MAKING ANY VOTING OR INVESTMENT DECISION, INVESTORS AND STOCKHOLDERS OF ONCONETIX ARE URGED TO CAREFULLY AND ENTIRELY READ THE REGISTRATION STATEMENT AND PROXY STATEMENT/PROSPECTUS REGARDING THE PROPOSED TRANSACTION AND ANY OTHER RELEVANT DOCUMENTS, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THOSE DOCUMENTS, IF AND WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT REALBOTIX, ONCONETIX, THE PROPOSED TRANSACTION, AND RELATED MATTERS.

A copy of the Registration Statement, Proxy Statement/Prospectus, as well as other relevant documents filed by Realbotix and Onconetix with the SEC, may be obtained free of charge, when they become available, at the SEC’s website at www.sec.gov. The information on Realbotix or Onconetix’s respective websites is not, and shall not be deemed to be, a part of this communication or incorporated into other filings either company makes with the SEC.

Participants in the Solicitation

Realbotix, Onconetix and certain of their respective directors, executive officers, and employees may be deemed to be participants in the solicitation of proxies in connection with the proposed transaction. Information about the directors and executive officers of Onconetix, their ownership of Onconetix common stock, and Onconetix’s transactions with related persons is set forth in the 10-K, as filed with the SEC on March 13, 2026, and other documents that may be filed from time to time with the SEC. Additional information about the directors and executive officers of Realbotix and Onconetix and other persons who may be deemed to be participants in the solicitation of stockholders of Onconetix in connection with the proposed transaction and a description of their direct and indirect interests will be included in the Proxy Statement/Prospectus related to the proposed transaction or other relevant materials, which will be filed with the SEC. These documents may be obtained free of charge, when they become available, at the SEC’s website at www.sec.gov and from Onconetix using the sources indicated above.

No Offer or Solicitation

This communication is for informational purposes only and is not intended to and does not constitute an offer to sell or the solicitation of an offer to buy or sell any securities or the solicitation of any proxy, vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act, or in a transaction exempt from the registration requirements of the Securities Act.

Forward-Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements (including, without limitation, the anticipated benefits and opportunities that may be generated by the proposed transaction described herein) are based on Onconetix’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, the occurrence of any event, change, or other circumstances that could give rise to the right of one or both of the parties to terminate the share exchange agreement; the possibility that the proposed transaction does not close when expected or at all because the conditions to closing are not satisfied on a timely basis or at all, including the failure to timely obtain stockholder approval for the proposed transaction from Onconetix’s stockholders, if at all; risks related to Onconetix’s continued listing on Nasdaq until closing of the proposed transaction; the outcome of any legal proceedings that may be instituted against Realbotix, Onconetix, or the combined company; the possibility that the anticipated benefits of the proposed transaction are not realized when expected or at all; the possibility that the vision, goals, and trajectory of the combined company are not timely achieved or realized or achieved or realized at all; the possibility that the proposed transaction may be more expensive or take longer to complete than anticipated, including as a result of unexpected factors or events; the diversion of management’s attention from ongoing business operations and opportunities; changes in Onconetix’s stock price before closing; and other factors that may affect future results of Realbotix, Onconetix, or the combined company. Onconetix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in Onconetix’s Annual Report on Form 10-K filed with the SEC on March 13, 2026 (the “10-K”) and periodic reports filed with the SEC on or after the date thereof. All of Onconetix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

Investor and Media Contact:
Onconetix, Inc.
201 E. Fifth Street, Suite 1900
Cincinnati, OH 45202
Phone: (513) 620-4101
Email: investors@onconetix.com

PEKIN, Ill., Sept. 14, 2026 (GLOBE NEWSWIRE) — Alto Ingredients, Inc. (NASDAQ: ALTO), a producer and distributor of renewable fuel, essential ingredients and specialty alcohols, today announced that management will take part in the H.C. Wainwright 28th Annual Global Investment Conference, conducting one-on-one meetings throughout the day on Tuesday, September 15, 2026.

About Alto Ingredients, Inc.
Alto Ingredients, Inc. (NASDAQ: ALTO) is a leading producer and distributor of renewable fuels, essential ingredients and specialty alcohols. Leveraging the unique qualities of its facilities, the company serves customers in a wide range of consumer and commercial products in the Health, Home & Beauty; Food & Beverage; Industry & Agriculture; Essential Ingredients; and Renewable Fuels markets. For more information, please visit www.altoingredients.com.

Media and Company IR Contact:
Michael Kramer, Alto Ingredients, Inc., 916-403-2755
Investorrelations@altoingredients.com 

IR Agency Contact:
Jody Burfening, Alliance Advisors Investor Relations, 212-838-3777
Investorrelations@altoingredients.com

First advance under second tranche brings total drawn under the DOE facility to $178 million and supports 4 GWh of annual battery manufacturing capacity in Western Pennsylvania

PITTSBURGH, Sept. 14, 2026 (GLOBE NEWSWIRE) — Eos Energy Enterprises, Inc. (NASDAQ: EOSE) (“Eos” or the “Company”), America’s leading innovator in designing, manufacturing, and providing zinc-based long-duration energy storage (LDES) systems sourced and manufactured in the United States, today announced it has received an $87 million first advance under the second tranche of its loan agreement with the U.S. Department of Energy’s (DOE) Office of Energy Dominance Financing (EDF).

The advance reimburses 80% of eligible costs associated with the Company’s Thorn Hill manufacturing facility in Warrendale, Pennsylvania. Eos has now drawn a total of approximately $178 million of its DOE facility since 2024.

Line 2 entered commercial production in June 2026 and is being ramped toward its designed annual manufacturing capacity of approximately 2 GWh. Upon completion of the planned relocation of line 1 to Thorn Hill, subject to lender approvals, Eos expects Thorn Hill to support approximately 4 GWh of annual manufacturing capacity across two lines.

“Loan funding from the Office of Energy Dominance Financing has been critical in scaling Eos,” said Alessandro Lagi, Chief Financial Officer of Eos. “This advance reimburses a significant portion of the investment we have already made in Line 2 and returns that capital to the balance sheet, giving us more room to invest in the business while maintaining a disciplined approach to growth.”

“Running two lines under one roof drives more efficient use of our engineering, support resources, and labor,” said John Mahaz, Chief Operating Officer of Eos. “This enables the operation to increase productivity and optimize manufacturing cost.”

Eos expects to create jobs across 4 shifts to staff Line 2 in the Western Pennsylvania facility. The line continues to ramp toward full production as additional shifts come online, consistent with the Company’s phased manufacturing scale-up strategy.

About Eos Energy Enterprises

Eos is accelerating the shift to American energy independence with positively ingenious solutions that transform how the world stores power. The Company’s BESS features the innovative Znyth™ technology, a proven chemistry with readily available non-precious earth components, that is the pre-eminent safe, non-flammable, secure, stable, and scalable alternative to conventional technology. The Company’s BESS is ideal for utility-scale, microgrid, commercial, and industrial long-duration energy storage applications (i.e., 4 to 16+ hours), and provides customers with significant operational flexibility to effectively address current and future increased grid demand and complexity. For more information about Eos (NASDAQ: EOSE), visit eose.com.

Contacts

Investors: ir@eose.com
Media: media@eose.com

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding the expected use and benefits of the loan proceeds; the continued development, installation, startup, operation, and ramp-up of Line 2; the expansion and scaling of Eos’ manufacturing operations and domestic manufacturing capacity; the timing and achievement of targeted production levels and annual manufacturing capacity; the anticipated staffing, hiring, and job creation associated with Line 2; the availability of future advances under the DOE-guaranteed loan facility; the receipt of any required lender or governmental approvals; and Eos’ ability to execute its growth strategy, and other statements that are not historical facts. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are based on our management’s current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.

Important factors that could cause actual results to differ materially include, among others, risks relating to Eos’ ability to satisfy the conditions applicable to future advances under the DOE-guaranteed loan facility; complete, commission, operate, and ramp Line 2 on the anticipated schedule and within the applicable budget; achieve targeted production rates, staffing levels, hiring objectives, and manufacturing capacity; manage construction, equipment, supply-chain, labor, startup, and operational risks; obtain and maintain required governmental and third-party approvals; comply with the DOE loan documents and other financing arrangements; maintain adequate liquidity and secure additional financing when needed; realize anticipated manufacturing efficiencies, productivity improvements, cost benefits, and operational synergies associated with consolidating manufacturing activities; and scale manufacturing operations, and other risks described in Eos’ filings with the Securities and Exchange Commission (“SEC”).

Additional information concerning these and other risk factors is contained in the Company’s filings with the SEC, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.

Forward-looking statements speak only as of the date they are made. Should one or more of these risks or uncertainties materialize or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Readers are cautioned not to put undue reliance on forward-looking statements, and, except as required by law, the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.